热门资讯> 正文

I-Mab Bizerma GAAP每股收益为-0.48美元

2026-04-08 05:26

新桥生物(NBP) 0

I-Mab Biopharma press release (NBP): FY GAAP EPS of -$0.48.
As of December 31, 2025, the Company had cash, cash equivalents, and short-term investments of $210.8 million. The Company’s current cash position is expected to support operations through 2028.

More on I-Mab Biopharma

NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration - Slideshow
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
Seeking Alpha’s Quant Rating on I-Mab Biopharma
Historical earnings data for I-Mab Biopharma
Financial information for I-Mab Biopharma

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。